Coloplast stock faces a DKK 465 target as Barclays stays Hold

Published on 10/08/2026 at 09:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coloplast stock generated DKK 21.482 billion in nine-month FY2025/26 revenue, while EBIT before special items was DKK 5.599 billion. The November 3, 2026 annual result is the next scheduled checkpoint.

Isometrische 3D-Grafik einer Wertschöpfungskette von Rohmaterial bis Distribution — Coloplast A/S (DK0060448595) und die Wertschöpfungskette der Medizintechnik werden hier isometrisch als übersichtliches Prozessdiagramm dargestellt, Illustration mit AI erstellt.

Coloplast stock (ISIN DK0060448595) was trading at DKK 426.10 on Nasdaq Copenhagen on October 8, 2026, while Barclays maintained a Hold rating and set a DKK 465.00 price target on October 5, 2026. The analyst stance puts the next test on execution rather than on a fresh change in the recommendation.

Barclays keeps a Hold view

According to Markets Insider on October 5, 2026, Barclays analyst Hassan Al-Wakeel kept the Hold rating and assigned a DKK 465.00 target. The target stands DKK 38.90 above the October 8 price, a 9.1 percent difference.

The same report described a Hold consensus with an average target of DKK 465.00. That gives the stock a defined valuation checkpoint, but the target remains below the 52-week high of DKK 631.40.

Revenue grows while margins matter

In its September 12, 2026 research, FactorsToday reported nine-month FY2025/26 revenue of DKK 21.482 billion, up 6 percent organically but 3 percent on a reported basis. EBIT before special items was DKK 5.599 billion, down 2 percent as reported and equal to a 26 percent margin versus 27 percent a year earlier.

The comparison explains the investor tension: operating demand remained positive, yet currency effects and a lower margin reduced the quality of reported growth. The period also included a DKK 3.0 billion Kerecis impairment, which makes adjusted performance and cash generation important alongside headline earnings.

November results set next checkpoint

Coloplast's financial calendar published on September 24, 2026, lists the annual 2026 results for November 3, 2026, at 12:05 p.m. CET, according to MFN. That release should clarify whether the 5 percent to 6 percent organic-growth outlook and 5 percent constant-currency EBIT-growth outlook remain appropriate.

For investors, the central question is whether chronic-care growth can offset pressure in wound biologics and preserve the 26 percent nine-month EBIT margin. Coloplast's medical technology portfolio remains tied to recurring ostomy, continence and urology demand, but the latest margin comparison shows why execution and capital discipline now carry equal weight.

Stock trades above yearly low

Coloplast stock was last at DKK 426.10 on Nasdaq Copenhagen at 9:54 a.m. CEST on October 8, 2026, down DKK 0.20 or 0.05 percent from the prior close. The session range was DKK 422.50 to DKK 426.30, while the 52-week range was DKK 369.70 to DKK 631.40.